Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lauren Burns

Nurse Practitioner Orland Park, IL Nurse Practitioner

NPI 1750881918 CMS profile 10567357

10745 165Th St, Orland Park, IL 60467

Open in the dashboard

General payments

$10,129

488 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Burns of Orland Park, IL is reported in the CMS Open Payments database as having received $10,129 across 488 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,716 73
2024 General $3,229 155
2023 General $1,929 97
2022 General $1,780 93
2021 General $1,474 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Burns
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lauren Burns were reported at $1,716. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lauren Burns Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,474 $135 $40–$426 $132
2022 $1,780 $152 $48–$470 $149
2023 $1,929 $166 $54–$529 $160
2024 $3,229 $173 $55–$556 $164
2025 $1,716 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,770 94 payments
  2. Corium, Inc. $975 42 payments
  3. ITI, Inc. $717 35 payments
  4. Axsome Therapeutics, Inc. $680 26 payments
  5. Teva Pharmaceuticals USA, Inc. $664 34 payments
  6. Janssen Pharmaceuticals, Inc $659 27 payments
  7. Otsuka America Pharmaceutical, Inc. $552 28 payments
  8. Lundbeck LLC $522 27 payments
  9. Alkermes, Inc. $488 24 payments
  10. Vanda Pharmaceuticals Inc. $480 15 payments
  11. Other $2,621 136 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,070 486 payments
  2. Education $59 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,500 82 payments
  2. Azstarys $975 42 payments
  3. Auvelity $680 26 payments
  4. CAPLYTA $648 32 payments
  5. ARISTADA Cns $488 24 payments
  6. ARISTADA Cns $488 24 payments
  7. FANAPT $480 15 payments
  8. LYBALVI $451 22 payments
  9. REXULTI $430 22 payments
  10. INGREZZA $406 15 payments
  11. Other $6,258 317 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

3,018

Median for Nurse Practitioner: 389

Drug cost

$304,216

Median for Nurse Practitioner: $21,885

Branded share of claims

19.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 22 $85,672
Austedo Deutetrabenazine Brand 15 $64,993
Vraylar Cariprazine Hcl Brand 29 $51,507
Lurasidone Hcl Generic 27 $15,920
Aripiprazole Generic 105 $14,300
Asenapine Maleate Generic 25 $11,055
Tranylcypromine Sulfate Generic 14 $5,521
Paliperidone Er Paliperidone Brand 31 $5,143
Bupropion Xl Bupropion Hcl Brand 190 $4,036
Atomoxetine Hcl Generic 22 $3,975

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $631
$631 29 —
Azstarys
  • Corium, Inc. $532
$532 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $174
  • Lundbeck LLC $85
$258 — —
Auvelity
  • Axsome Therapeutics, Inc. $217
$217 — —
Dyanavel XR
  • Tris Pharma Inc $201
$201 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

488 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record